Oculus Innovative Sciences Inc (NASDAQ:OCLS)
The Company has developed and it manufactures and markets, a family of products intended to prevent and treat infections in chronic and acute wounds.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Growth prospects
Recs
down because the market is down long term could be a winner
Recs
When this company went public back in 2007, it's share price peaked at around $11. It has steadily gone down since then and now typically trades at a little over $1.
What's interesting about this is that it's revenue has actually grown from $94,000 in 2004 to $9,754,000 in 2011. Expenses have not grown with the revenue, it has high profit margins, and excellent management.
This stock is dramatically undervalued, currently selling at the bargain price of $1.26. One day this company is going to catch Wall Street's eye, and when that happens we'll see the share price go through the roof.
Recs
totally under the radar. positive free cash flow per share. Huge market with disruptive technology. Medicare won't pay for wound infections and this company has a reasonable remedy. I own this stock.
Recs
This company has had some problems in the past, but it sells a brand that is important in the healthcare field and is only going to expand in business as people look for cheaper alternatives to expensive prescription medications.
Recs
wonder if new acne meds do good in mexico? I actually hope they market to military for wound treatments.
Recs
Amazing new products in the medical field.
Recs
Announcing their final FDA approval in September and the distribution deals will follow. This stock is a 10 bagger over the next year.
Recs
Oculus Innovative Sciences, Inc. is a medical technology company focused on the development, manufacture and marketing of a family of products intended to help prevent and treat infection in acute and chronic wounds. Oculus’ platform technology, called Microcyn
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 9 of 9